Replies to post #320998 on Avid Bioservices Inc (CDMO)

[revenue_monster]

he did say encouraged, believe and potential

While adoptive T cell transfer remains one of the most exciting new approaches to treating cancer, to date the toxicity associated with the treatment has limited its potential. We are encouraged that these study results showed that the combination of anti-PS and adoptive T cell treatment led to enhanced anti-tumor effect without any evidence of additional off-target side effects,” said Taha Merghoub, Ph.D., co-director of the Ludwig Collaborative Laboratory at MSK. “We believe that these findings may support potential applications for this combination in solid tumors in the future.”

[InternetForumUser]

Yes it does. It is the same as the KOLs and how they would have a positive impact on the value of Bavituximab. It was a complete joke because only one or two of the KOLs actually mentioned the drug.

I am fairly confident that Wolchock and whatever he is doing will be pretty meaningless.

I just hope that PPHM gets some money for the IP.